Get the Stockscreener App
48.83
2.89%
1.37
Vera Therapeutics Inc Stock (VERA) Latest News
Objective long/short (VERA) Report - Stock Traders Daily
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Vera Therapeutics Grants 161,000 Share Awards to New Chief Legal Officer | VERA Stock News - StockTitan
Wells Fargo Initiates Coverage of Vera Therapeutics (VERA) with Overweight Recommendation - MSN
Vera Therapeutics initiated with an Overweight at Wells Fargo - MSN
Vera Therapeutics (NASDAQ:VERA) Coverage Initiated at Wells Fargo & Company - MarketBeat
GSA Capital Partners LLP Has $535,000 Stock Holdings in Vera Therapeutics, Inc. (NASDAQ:VERA) - MarketBeat
Wall Street Analysts Think Vera Therapeutics (VERA) Could Surge 27.26%: Read This Before Placing a Bet - MSN
Calif. Biotech Firm Vera Taps Veteran Chief Legal Officer - Law360
First Turn Management LLC Increases Stock Holdings in Vera Therapeutics, Inc. (NASDAQ:VERA) - MarketBeat
Vera Therapeutics Appoints Jason S. Carter as Chief Legal Officer - GlobeNewswire
Vera Therapeutics Appoints Former Kite Pharma Legal Head as Chief Legal Officer | VERA Stock News - StockTitan
Vera Therapeutics Appoints Jason S. Carter as Chief Legal Officer By Investing.com - Investing.com Canada
(VERA) Proactive Strategies - Stock Traders Daily
COMMODORE CAPITAL LP Adjusts Stake in Vera Therapeutics Inc - GuruFocus.com
Kynam Capital Management, LP Increases Stake in Vera Therapeutics Inc - GuruFocus.com
500: Something went wrong - Investing.com India
Vera Therapeutics stock soars to all-time high of $50.98 - Investing.com
Vera Therapeutics stock soars to all-time high of $50.98 By Investing.com - Investing.com Australia
Vera Therapeutics (NASDAQ:VERA) Reaches New 1-Year HighHere's What Happened - MarketBeat
FMR LLC Reduces Stake in Vera Therapeutics Inc - GuruFocus.com
Vera Therapeutics Partners with University of Michigan on the NEPTUNE Match Project and PIONEER Study - The Manila Times
Vera Therapeutics Awards $45.17 Stock Options to New Hires in Growth Push | VERA Stock News - StockTitan
Vera Therapeutics (NASDAQ:VERA) Posts Quarterly Earnings Results, Misses Expectations By $0.21 EPS - MarketBeat
Vera Therapeutics to Participate at Upcoming Investor Conferences - GlobeNewswire
Vera Therapeutics to Present at Two Major Healthcare Investor Conferences | VERA Stock News - StockTitan
Vera Therapeutics (NASDAQ:VERA) Price Target Raised to $38.00 - MarketBeat
Vera Therapeutics Advances in Autoimmune Treatment - TipRanks
Vera Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results - The Manila Times
Vera Therapeutics, Inc. (NASDAQ:VERA) Given Average Rating of "Buy" by Brokerages - MarketBeat
JPMorgan Chase & Co. Boosts Vera Therapeutics (NASDAQ:VERA) Price Target to $75.00 - MarketBeat
Trading (VERA) With Integrated Risk Controls - Stock Traders Daily
Vera Therapeutics (NASDAQ:VERA) Shares Up 7.3%Here's Why - MarketBeat
Vera Therapeutics announces proposed public offering of class A common stock - MSN
FORUS Therapeutics Inc. and PharmaEssentia Corporation Have Entered Into an Exclusive Licensing Agreement for The Registration and Distribution of BESREMi(R) (ropeginterferon alfa-2b) for The Treatment of polycythemia vera (PV), in Canada - Newsfile
Vera Therapeutics director Beth Seidenberg sells shares for $720,493 - Investing.com India
Vera Therapeutics director Beth Seidenberg sells shares for $720,493 By Investing.com - Investing.com Canada
Vera Therapeutics (NASDAQ:VERA) Sees Large Volume IncreaseHere's What Happened - MarketBeat
Vera Therapeutics (NASDAQ:VERA) PT Raised to $64.00 at Guggenheim - Defense World
Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock - GlobeNewswire
Vera Therapeutics (NASDAQ:VERA) Shares Gap DownHere's Why - MarketBeat
Vera Therapeutics price target raised to $64 from $56 at Guggenheim - Yahoo Finance
SEC Form 424B5 filed by Vera Therapeutics Inc. - Quantisnow
Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock - The Manila Times
Vera Therapeutics (NASDAQ:VERA) Price Target Raised to $64.00 - MarketBeat
Vera Therapeutics' Atacicept Shows Sustained, Substantial Improvement In Kidney Function For Patients At Almost Two Years - AOL
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):